InvestorsHub Logo
Followers 19
Posts 334
Boards Moderated 0
Alias Born 07/25/2016

Re: None

Wednesday, 10/11/2017 5:11:52 PM

Wednesday, October 11, 2017 5:11:52 PM

Post# of 48316
https://www.sitcancer.org/2017/abstracts/titles/late-breaking
Oncolytic Viruses and Intratumoral Therapies

P524

Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1



Alain P. Algazi1, Katy K. Tsai1, Michael D. Rosenblum1, Robert Andtbacka2, Carmen Ballesteros-Merino3, Shawn Jensen3, Carlo B. Bifulco3, Bernard A. Fox3, SuFey Ong4, Alessandra Cesano4, Joseph Beechem4, Chris Twitty5, Jean S. Campbell5, Erica Browning5, Reneta Talia5, Shawna A. Shirley5, Mai H. Le5, Robert H. Pierce5, Sharron Gargosky5, Adil I. Daud1

1University of California 2University of Utah 3Providence Portland Medical Center 4NanoString Technologies, Inc. 5OncoSec Medical Incorporated